Literature DB >> 26051238

Toxic epidermal necrolysis induced by vemurafenib.

A Lapresta1, A Dotor2, C González-Herrada3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26051238     DOI: 10.1016/j.ad.2015.03.008

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


× No keyword cloud information.
  4 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

Review 2.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 3.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

4.  Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

Authors:  J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover
Journal:  Invest New Drugs       Date:  2021-01-03       Impact factor: 3.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.